Plague drugs report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plague and features dormant and discontinued projects.
Key Targets in the Plague Pipeline Market
The key targets in the plague pipeline market are Peptidyl Prolyl Cis Trans Isomerase FKBP5, Protein Tyrosine Phosphatase, Yersinia pestis Protein Tyrosine Phosphatase YopH, and Yersinia pestis Virulence Associated V Antigen.
Key MoA in the Plague Pipeline Market
The key MoA in the plague pipeline market are Protein Tyrosine Phosphatase Inhibitor and Yersinia pestis Protein Tyrosine Phosphatase YopH Inhibitor.
Key RoA in the Plague Pipeline Market
The key RoA in the plague pipeline market are oral, intramuscular, subcutaneous, intravenous, sublingual, and topical. Oral has the highest number of pipeline products in the plague pipeline market.
Plague Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Type in the Plague Pipeline Market
The key molecule type in the plague pipeline market are subunit vaccine, recombinant vector vaccine, live attenuated vaccine, small molecule, monoclonal antibody, and vaccine. Subunit vaccine has the highest number of pipeline products in the plague pipeline market.
Plague Pipeline Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Companies in the Plague Pipeline Market
The key companies in the plague pipeline market are Enesi Pharma Ltd, FasCure Therapeutics LLC, Greffex Inc, iBio Inc, Mapp Biopharmaceutical Inc, Norwell Inc, Opal Biosciences Ltd, and Prokarium Ltd.
Market report overview
| Key targets | Peptidyl Prolyl Cis Trans Isomerase FKBP5, Protein Tyrosine Phosphatase, Yersinia pestis Protein Tyrosine Phosphatase YopH, and Yersinia pestis Virulence Associated V Antigen |
| Key MoA | Protein Tyrosine Phosphatase Inhibitor and Yersinia pestis Protein Tyrosine Phosphatase YopH Inhibitor |
| Key RoA | Oral, Intramuscular, Subcutaneous, Intravenous, Sublingual, and Topical |
| Key molecule type | Subunit Vaccine, Recombinant Vector Vaccine, Live Attenuated Vaccine, Small Molecule, Monoclonal Antibody, and Vaccine |
| Key companies | Enesi Pharma Ltd, FasCure Therapeutics LLC, Greffex Inc, iBio Inc, Mapp Biopharmaceutical Inc, Norwell Inc, Opal Biosciences Ltd, and Prokarium Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Plague (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Plague (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Plague (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Plague (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Plague (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Plague (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Plague (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Stakeholders
Table of Contents
Tables
List of Tables
Number of Products under Development for Plague, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Plague – Pipeline by Enesi Pharma Ltd, 2022
Plague – Pipeline by FasCure Therapeutics LLC, 2022
Plague – Pipeline by Greffex Inc, 2022
Plague – Pipeline by iBio Inc, 2022
Plague – Pipeline by Mapp Biopharmaceutical Inc, 2022
Plague – Pipeline by Norwell Inc, 2022
Plague – Pipeline by Opal Biosciences Ltd, 2022
Plague – Pipeline by Prokarium Ltd, 2022
Plague – Dormant Projects, 2022
Plague – Discontinued Products, 2022
Graphs
List of Figures
Number of Products under Development for Plague, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022









